强生医学技术

2023年7月25日

Optrell导管是一种高密度的诊断导管映射重做AFib消融情况下,持续的心房纤维性颤动,心房心动过速,室性心动过速的产品图像Optrell映射导管。(来源:公关新闻专线/ Biosense韦伯斯特,Inc .)强生医学技术的Biosense韦伯斯特也推出了其OPTRELL映射导管与TRUEref技术由纸箱3系统在美国。Biosense韦伯斯特设计Optrell导管作为高密度诊断导管。设备据说小电极排列在一个固定的数组形成来生成一个高清电生理学的映射复杂心律失常的情况下。OPTRELL TRUEref技术,获得美国食品和药物管理局(FDA) 510年的2022 (k)间隙,可以映射重做AFib消融情况下,持续性心房纤颤(AFib),心房心动过速和室性心动过速。根据强生医学技术单元,分布对称的导管有48个电极以及六样条函数。它结合纸箱3系统提供的信息以及高分辨率方向映射。OPTRELL导管还包含电极和电极间距紧张紧凑,从而提高信号的分辨率和改善心脏的地图。临床医生可以更好地确定心律失常的位置使用这些高清地图,也帮助他们创造更多的成功消融计划,强生的单位说。Biosense韦伯斯特主席加斯米娜布鲁克斯说:“OPTRELL映射导管轮出Biosense韦伯斯特诊断映射组合,为医生提供一组全面的工具,结合我们的纸箱3映射系统,诊断和治疗心律失常。 “This is the latest example of the continued commitment of Biosense Webster to providing clinicians with innovative tools to improve efficiency and effectiveness of procedures and quality of care for patients.” The CARTO 3 system, which powers the OPTRELL Mapping Catheter, provides local conduction vectors that show the direction and speed of the electrical impulses travelling through the heart in real-time. By using these local conduction vectors, doctors can identify gaps in ablation lesions and get better insights into complex circuits and mechanisms, Biosense Webster said. This will help clinicians to locate areas that require ablation and deliver more efficient treatment in less time. The OPTRELL Mapping Catheter with TRUEref technology is expected to be available commercially in Japan later this year. Do you have interesting content to share with us? Enter your email address so we can get in touch. Related Article